Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rissmann

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
British Journal of Clinical Pharmacology|March 25, 2021
Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et alRobert Rissmann, Rob Zuiker
British Journal of Clinical Pharmacology|April 26, 2019
Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?Robert Rissmann, Elemer Szabadi
British Journal of Clinical Pharmacology|January 26, 2019
Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration databaseRikje Ruiter, Jacobus Burggraaf, Robert Rissmann
The British Journal of Dermatology|August 23, 2022
Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic waveDeepak M W Balak, Robert Rissmann
Chemistry and Physics of Lipids|November 11, 2008
Long periodicity phase in extracted lipids of vernix caseosa obtained with equilibration at physiological temperatureRobert Rissmann, Gert Gooris, Maria Ponec, et al.
British Journal of Clinical Pharmacology|June 1, 2011
TolvaptanEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
LomitapideSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 31, 2015
MirabegronSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 8, 2011
Rilonacept and canakinumabEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
BedaquilineSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
British Journal of Clinical Pharmacology|March 25, 2021
Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et alRobert Rissmann, Rob Zuiker
British Journal of Clinical Pharmacology|April 26, 2019
Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?Robert Rissmann, Elemer Szabadi
British Journal of Clinical Pharmacology|January 26, 2019
Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration databaseRikje Ruiter, Jacobus Burggraaf, Robert Rissmann
The British Journal of Dermatology|August 23, 2022
Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic waveDeepak M W Balak, Robert Rissmann
Chemistry and Physics of Lipids|November 11, 2008
Long periodicity phase in extracted lipids of vernix caseosa obtained with equilibration at physiological temperatureRobert Rissmann, Gert Gooris, Maria Ponec, et al.
British Journal of Clinical Pharmacology|June 1, 2011
TolvaptanEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
LomitapideSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 31, 2015
MirabegronSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
British Journal of Clinical Pharmacology|March 8, 2011
Rilonacept and canakinumabEline A Dubois, Robert Rissmann, Adam F Cohen
British Journal of Clinical Pharmacology|February 24, 2015
BedaquilineSebastiaan C Goulooze, Adam F Cohen, Robert Rissmann
Pageof 10